Clinical Data Demonstrates Accuracy of Technology That Can Predict Disease Progression Using Prostatectomy Tissue after Surgery
YONKERS, N.Y., Aug. 26, 2008-Aureon Laboratories, a specialized laboratory dedicated to advancing personalized cancer treatment through predictive pathology, today announced that data from a clinical study published in the Journal of Clinical Oncology (JCO) supports the company’s Systems Pathology approach underlying Aureon’s prostatectomy-based test, Prostate Px®.
“The Journal of Clinical Oncology study is the latest peer-reviewed study that validates the Systems Pathology approach used in our prostatectomy-based test,” said Dr. Vijay Aggarwal, president and chief executive officer of Aureon Laboratories.
The article reviews data obtained in a cohort of 758 men with prostate cancer. Researchers at Aureon, Memorial Sloan-Kettering Cancer Center and Columbia University examined prostatectomy tissue samples using machine learning tools to develop a model that includes dominant prostatectomy Gleason grade, lymph node involvement and cellular and molecular features from prostatectomy tissue.
On a population of 373 patients, the model had a sensitivity of 90 percent and specificity of 91 percent for predicting clinical failure within five years of prostatectomy. The model was then externally validated using data from 385 patients and yielded a sensitivity of 84 percent and specificity of 85 percent for predicting clinical failure. Clinical failure is defined as evidence of metastasis, an increasing PSA in a castrate state or death attributed to prostate cancer. The study found that integrating clinicopathologic variables with imaging and biomarker data resulted in an accurate tool for predicting clinical failure five years after prostatectomy.
Aureon’s proprietary Systems Pathology is also the technological foundation behind Aureon’s latest test, Prostate Px+, which uses biopsy tissue at the time of diagnosis to predict prostate cancer progression and disease recurrence.
About Aureon Laboratories
Aureon Laboratories' mission is to enable personalized patient care through predictive pathology. Aureon has developed a high throughput systems pathology technology platform to predict individual clinical outcomes through the interrogation of tissue. The platform generates and analyzes an integrated, digital view of clinical findings, tissue micro-anatomy and tissue molecular pathology to determine which combination of features predicts specified individual clinical outcomes. Allied with major cancer centers, Aureon operates a CLIA certified and CAP accredited laboratory that provides predictive pathology services to the practicing physician. For more information about Aureon, go to www.aureon.com or call 1-888-SYS-PATH.